Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities
Eligible age
10–17 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Correct use of daily medications containing inhaled corticosteroids is key for asthma control, yet children with intellectual and developmental disabilities (IDD) face additional barriers to proper inhaler use. Smart inhalers, a novel technology that provides guidance and immediate feedback on inhaler use techniques, have been shown to enhance correct medication administration in the typically developing pediatric population, but their effectiveness has not been evaluated on the pediatric IDD population. This study aims to investigate whether daily application of smart inhalers (1) is feasible and acceptable in the IDD population, (2) improves the rate of correct medication administration, and (3) results in improvement in lung function. This effort aims to promote better asthma management in the IDD population.
Sponsor: Children's Hospital Los Angeles
You may qualify if…
- ✓ Adolescents ages 10-17 years
- ✓ Diagnosis of mild-to-moderate intellectual disability: ICD-10: F70-F71 and/or diagnosis of developmental disability, including autism: ICD-10: F80-89
- ✓ Diagnosis of moderate-to-severe asthma or moderate or severe unspecified asthma: ICD-10: J45.40-J45.909
- ✓ Parent/legal guardian is willing to answer questions about their child.
- ✓ Parent/legal guardian and adolescent must have the ability to understand study procedures and to comply with them for the entire length of the study
- ✓ English or Spanish-speaking participants
- ✓ Not involved in other studies using digital inhalers
- ✓ Males and females of reproductive capability will be enrolled: contraception is not necessary or required.
You may not qualify if…
- ✕ Health status or any clinical conditions: Limited life expectancy, co-existing disease or other characteristics that precludes appropriate diagnosis, treatment, or follow-up in the trial.
- ✕ Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Where it's recruiting
Los Angeles
Source: ClinicalTrials.gov · NCT06783101 · last updated 2025-01-20